Longeveron Secures $16.79M in Highly Dilutive Private Placement at Deep Discount, Extends Runway

summarizeSummary

Longeveron Inc. closed the initial tranche of a private placement, raising $16.79 million at a deep discount and with significant dilution, extending its cash runway into Q4 2026. The financing includes common stock, convertible preferred stock, and warrants, with a potential second tranche of $15 million tied to clinical milestones.

check_boxKey Events · Financing and Capital Events · LGVN

• Initial Private Placement Closing

  Longeveron Inc. completed the initial closing of a private placement on March 11, 2026, raising approximately $15.9 million in gross proceeds. This follows the announcement of the private placement on March 10, 2026.

• Highly Dilutive Terms

  The initial closing involved the issuance of 6,013,384 shares of common stock at $0.52 per share and 11,873.04 shares of Series A Preferred Stock (convertible into 22,832,770 common shares) at $1,000 per preferred share. Additionally, placement agent warrants for 2,019,231 common shares at an exercise price of $0.65 per share were issued. The pro forma outstanding shares after this tranche, including full conversion and warrant exercise, are approximately 54.13 million.

• PRV Interest Sold

  The company also sold an interest in 50% of the proceeds from a potential future Rare Pediatric Disease Priority Review Voucher (PRV) for $890,000, providing immediate cash but foregoing future upside from this asset.

• Cash Runway Extended

  The net proceeds from the initial closing are expected to fund operations into the fourth quarter of 2026, supporting ongoing clinical and regulatory development of laromestrocel.

auto_awesomeAnalysis · LGVN · Life Sciences

Longeveron Inc. has finalized the terms of a significant private placement, securing $16.79 million in gross proceeds from an initial closing. This capital raise is critical for the company, extending its cash runway into the fourth quarter of 2026 and funding ongoing clinical development. However, the financing comes at a substantial cost to existing shareholders, involving significant dilution and a deep discount to the current market price. The offering price of $0.52 per share for common stock and convertible preferred stock is considerably below the current stock price of $0.84. The initial closing alone results in approximately 30.87 million new shares (common stock, preferred stock conversion, and placement agent warrants), leading to a pro forma outstanding share count of 54.13 million. This massive dilution, coupled with the deep discount, indicates the company's urgent need for capital, especially in light of its recent Nasdaq non-compliance and proposal for a reverse stock split. The deal also includes a milestone-driven second closing for an additional $15 million, contingent on positive Phase 2b clinical trial results and a higher stock price threshold, adding future uncertainty and potential further dilution. Additionally, the company sold 50% of the proceeds from a potential future Rare Pediatric Disease Priority Review Voucher for $890,000, monetizing a future asset at a discount.